Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
This is an international, first-in-human, multicenter, open-label Phase 1/2 study to evaluate
the safety profile, tolerability of IPH6501, and determine the recommended phase 2 dose
(RP2D) for patients with B-Cell non-Hodgkin lymphoma.